Small Molecule-Conjugated Carrier Protein

Creative Diagnostics leverages cutting-edge technology platforms to deliver pre-constructed, rigorously quality-controlled, ready-to-use standard bioconjugates, helping you bypass complex conjugation process development and validation cycles. We offer Small Molecule–Carrier Protein Conjugates (SM-CCPs), where biologically active small molecules—such as haptens, drugs, fluorescent probes, and biotin—are covalently linked to engineered and optimized carrier proteins through precise and stable chemical methods. Each product is designed to address critical challenges small molecules face in application, including low solubility, poor stability, weak immunogenicity, or lack of targeting specificity.

Product Features

Our SM-CCPs product line is built on well-established scientific principles. The carrier proteins significantly improve the pharmacokinetic properties of the attached small molecules—for instance, by extending their circulation half-life in vivo, enhancing their immunogenicity, or enabling specific tissue targeting. We offer a range of classic and innovative combinations of various small molecule ligands with different carrier proteins to cover common research needs. Each batch is accompanied by key characterization data—such as carrier protein type, small molecule ligand information, average conjugation ratio, molecular weight range, and solvent system—ensuring you have a clear understanding of the product.

Applications

• Therapeutic Vaccines and Antibody Development
  One of the most classic and core applications of SM-CCPs lies in the field of therapeutic vaccines and antibody generation. By conjugating small-molecule haptens—which are typically poorly immunogenic on their own, such as hormones, neurotransmitters, environmental pollutants, or drug molecules—to a suitable carrier protein (e.g., KLH), immune tolerance can be successfully overcome. This process induces the production of high-titer, highly specific antibodies. These antibodies are not only valuable for downstream detection and analysis, but also form the foundation for developing therapeutic vaccines targeting conditions such as addiction, cancer, and autoimmune diseases.
• Targeted Drug Delivery and Pharmacokinetic Studies
  In innovative drug discovery, SM-CCPs serve as an ideal model system for studying targeted delivery strategies and long-circulating systems. For example, conjugating a drug molecule to HSA can be used to mimic and investigate HSA-mediated passive targeting effects—such as tumor tissue accumulation via the enhanced permeability and retention (EPR) effect—and to evaluate the stability, distribution, and clearance rates of the conjugate in vivo. These studies provide critical data for the design of true antibody-drug conjugates (ADCs) or protein-drug conjugate precursors.
• High-Sensitivity Diagnostic Reagent Development
  In immunoassays, using standardized, pre-conjugated products—such as reporter molecules (enzymes, fluorescent dyes, biotin) or competitive antigens (small molecule-carrier protein conjugates)—can significantly streamline and standardize the development process for diagnostic kits.
• Cell Labeling and Imaging Research
  Conjugating specific fluorescent probes or biotin to a carrier protein results in substantially enhanced signal intensity compared to free small molecules and improves retention on cell or tissue surfaces. Such products are useful in flow cytometry, immunofluorescence staining, or in vivo imaging, enabling high-contrast labeling and tracking of specific cell surface receptors or biomarkers. This provides a powerful visualization tool for fundamental life science research.